Amicus Therapeutics is a publicly traded firm biopharmaceutical company headquartered in Cranbury, New Jersey. Before the company went public, it was funded by a host of different venture capital firms like Radius Ventures, New Enterprise Associates, and Canaan Partners. The focus of Amicus Therapeutics is on rare and orphan diseases, particularly the set of disorders collectively known as the lysosomal storage disorders. The platform that the company adheres to in its development is Chaperone-Advanced Replacement Therapy, also referred to as CHART. Amicus Therapeutics is focused on the development of enzyme replacement therapies as well through its product development platform. Presently, Amicus Therapeutics doesn’t manufacture but rely on contract manufacturing.
The company previously had just one research site in New Jersey, but in 2008, the company opened its second research base in San Diego. The company was funded by the Michael J Fox Foundation and the David Geffen School of Medicine at UCLA in the year 2010 and received a grant from the former organization of $500,000 (GoogleFinance). The Alzheimer’s Drug Discovery Foundation also provided the grant of $210,000 in 2010. As the world of medicine continues to improve and expand, it is essential for the biotechnology firms to do their part and devise ways to find a cure for the diseases that are making the lives of millions of kids and adults miserable across the globe. The biotechnology companies are equipped with the knowledge and the tools as well as the expertise needed to find ways to cure and control various rare and orphan diseases, which is what the Amicus Therapeutics is doing.
The principal product provided by Amicus Therapeutics is Migalastat, which is used to treat people who are in the later stage of suffering from Fabry disease. Amicus Therapeutics understands that science plays a huge role in transforming the field of medicine and ensures that it continues to develop therapies that help in treating rare and orphan diseases. Some of the diseases that Amicus Therapeutics is active working on to find its cure are Fabry Diseases, Pompe Disease, genetic connective skin disorder, and Lysosomal Storage Disorder. The company continues to make massive investments in research and development to strengthen and advance its research-based activities.
Check out Amicus Therapeutics on Twitter